Zhong Guo Jing Ji Wang·2025-12-08 09:22Core Viewpoint - Tianxin Pharmaceutical (603235.SH) is currently trading at 27.10 yuan, reflecting a decline of 1.06% and is in a state of share price decline since its IPO [1] Group 1: IPO Details - Tianxin Pharmaceutical was listed on the Shanghai Stock Exchange on July 12, 2022, with an initial public offering of 43.78 million shares, accounting for 10.00% of the total share capital post-issue, at a price of 36.88 yuan per share [1] - On its first trading day, the stock reached a peak price of 53.11 yuan, marking the highest point since its listing, but has since experienced a downward trend [1] Group 2: Fundraising and Use of Proceeds - The total amount raised from the IPO was 1,614.61 million yuan, with a net amount of 1,517.23 million yuan after deducting issuance costs, which was 880.51 million yuan less than the originally planned fundraising amount of 2,397.74 million yuan [1] - The funds were intended for projects including the construction of Vitamin A, Vitamin B5, cholesterol, and 25-hydroxyvitamin D3 production facilities, sales network and smart factory projects, corporate research institute projects, and to supplement working capital [1] Group 3: Underwriting and Fees - The underwriting institution for this issuance was CITIC Securities, with representatives Ding Yuan and Fang Chong [1] - The total issuance costs (excluding VAT) amounted to 97.37 million yuan, with CITIC Securities receiving 70.77 million yuan in underwriting and sponsorship fees [1]